UK Regulator Censures Theramex for Systemic Failures in HRT Provision

Theramex, a prominent UK producer of hormone replacement therapy (HRT) drugs, has been publicly reprimanded by the Prescription Medicines Code of Practice Authority (PMCPA) for significant compliance failures that jeopardized patient safety. The PMCPA's findings highlighted that Theramex breached compliance standards, including the failure to update crucial prescribing information for its products, Evorel and Intrarosa, some of which had not been revised for several years. Notably, the prescribing information did not clearly indicate that Intrarosa should not be used during pregnancy.

The Guardian

The PMCPA's investigation was prompted by whistleblower reports from Theramex employees, who raised concerns about incomplete prescribing information and inadequate side-effect disclosures for Evorel, a widely prescribed transdermal HRT patch containing estradiol. In the 2024/25 financial year, over 250,000 Evorel patches were issued, contributing to nearly 10 million items of estradiol prescribed overall. The PMCPA identified 21 breaches of the Association of the British Pharmaceutical Industry (ABPI) code of practice, stating that these violations not only endangered patient safety but also diminished public confidence in the pharmaceutical industry.

The Guardian

In response to the PMCPA's censure, Theramex announced its decision to withdraw from the PMCPA's self-regulatory framework, opting instead to be regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Theramex's spokesperson emphasized the company's commitment to ethical standards and patient safety, stating that they had undertaken a comprehensive review of their compliance framework and commissioned an independent external audit. The spokesperson noted that this shift would allow Theramex to focus resources on maintaining high ethical standards while adhering to UK medicines legislation.

The Guardian

Julian Beach, the MHRA's executive director of healthcare quality and access, expressed disappointment over Theramex's departure from the PMCPA, underscoring that the MHRA retains the authority to investigate and act on safety concerns regarding medicines. He affirmed that leaving the PMCPA does not exempt Theramex from scrutiny, as breaches of regulations can lead to criminal offenses.

The Guardian

Critics have voiced concerns regarding Theramex's decision to exit the PMCPA's jurisdiction, arguing that this move undermines the self-regulatory system designed to uphold higher standards than those mandated by law. Dr. Amit Aggarwal, medical director of the ABPI, stated that Theramex had "fallen seriously short" of expected standards, reinforcing the necessity for regulatory oversight to protect patient safety.

The Guardian

The PMCPA's reprimand of Theramex highlights critical issues surrounding compliance and patient safety in the pharmaceutical industry. As Theramex transitions to MHRA oversight, the implications of this regulatory shift will be closely monitored by both industry stakeholders and patient advocacy groups.

The Guardian